ReviewInternational journal of molecular sciences2020
Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH).
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Identification of shared biomarkers in obesity and non-alcoholic fatty liver disease: a comprehensive analysis of Mendelian randomization and transcriptomic data.Frontiers in nutrition · 2026Article
- Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics andiScience · 2024Article
- An Introduction to Analytical Challenges, Approaches, and Applications in Mass Spectrometry-Based Secretomics.Molecular & cellular proteomics : MCP · 2023Review
- Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2022Article
- Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction.Frontiers in cardiovascular medicine · 2022Review
- Emerging roles of PHLPP phosphatases in metabolism.BMB reports · 2021Review
- Anti-fibrotic treatments for chronic liver diseases: The present and the future.Clinical and molecular hepatology · 2021Review
- Review
- Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.